Changzhou Jintan Synthetic Biology Industrial Park Opens with the Launch of BGI Blue Rainbow Biomedical Incubator

“Pioneering in Jintan, Innovating for a Blue Future.” On September 26, the opening ceremony of the Changzhou Jintan Synthetic Biology Industrial Park (hereinafter referred to as the “Synthetic Biology Industrial Park”) and the inauguration ceremony of the BGI Blue Rainbow Jintan Biomedical Incubator (hereinafter referred to as the “Blue Rainbow Jintan Incubator”) were successfully concluded. At the event, the Changzhou BGI Songhe Venture Capital Fund (hereinafter referred to as the “Changzhou BGI-Songhe Fund”) and the first batch of incubation projects at the Blue Rainbow Jintan Incubator also completed their signing ceremonies.

Address by Xu Xun, Executive Director of BGI Group and Dean of Shenzhen BGI Research

At the opening of the event, Xu Xun, Executive Director of BGI Group and Dean of Shenzhen BGI Research Institute, took the stage to deliver a speech. Dean Xu noted that although synthetic biology is still in its early stages of scientific research, it will serve as a significant driving force in China’s medium- and long-term biotechnology roadmap under the 14th Five-Year Plan. He expressed confidence that the field will rapidly take root and flourish, progressing seamlessly “from scientific research to technology and then to industry.” He expressed hope that the Changzhou Jintan District Synthetic Biology Industrial Park would leverage BGI’s domestically produced, large-scale, high-throughput synthesis platform to build an ecosystem encompassing the entire upstream and downstream synthetic biology value chain. This initiative aims to further advance the biomedical and life health industries and establish a industrial cluster valued at tens of billions of yuan.

Changzhou Jintan Synthetic Biology Industrial Park Holds Inauguration Ceremony

Jiang Pengju, Vice Mayor of the Changzhou Municipal People’s Government in Jiangsu Province; Xu Yawei, Deputy Secretary of the Jintan District Committee and District Mayor of Changzhou City, Jiangsu Province; and Xu Xun, Executive Director of BGI Group and Dean of Shenzhen BGI Research Institute, jointly took the stage to complete the opening ceremony of the Changzhou Jintan Synthetic Biology Industrial Park.

BGI Blue Rainbow Jintan Biomedical Incubator Inauguration Ceremony

Yang Jian, Member of the Standing Committee of the Jintan District Committee and Secretary of the Party Working Committee of Jiangsu Jintan Economic Development Zone; Li Guoqiang, Deputy Director of Changzhou Science and Technology Bureau; Li Dongying, Director of Jintan District Science and Technology Bureau; Yang Shuang, Executive Vice President of BGI Group, Chief Representative for the Eastern Region, and Chairman of Blue Rainbow; Shen Yue, Chief Scientist of Synthetic Biology at BGI-Shenzhen Institute of Life Sciences and Director of BGI Institute of Engineering Biology at Dangyang Lake; and Zhao Weiwen, General Manager of Blue Rainbow, jointly took the stage to launch the BGI Blue Rainbow Jintan Biomedical Incubator.

Signing Ceremony of Changzhou Huada Songhe Venture Capital Fund

In the presence of representatives from all parties, Changzhou Venture Capital Group, Jintan Holdings, SV Capital, and BGI Group jointly signed an agreement to establish the Changzhou BGI SV Venture Capital Fund.

Signing Ceremony for the Blue Rainbow Jintan Incubator Project

Zhao Weiwen, General Manager of Blue Rainbow, signed agreements with representatives of the first batch of high-quality incubatee enterprises at the Blue Rainbow Jintan Incubator.

Changzhou municipal leaders, representatives of Sinopharm Capital, and guests at the event jointly witnessed this significant moment.

Zeng Xiaoyu, Managing Partner of BGI-Songhe Life Sciences Fund

The event also featured a keynote address by Zeng Xiaoyu, Managing Partner of BGI-Sinovo Life Sciences Fund, titled “Innovative Growth and Investment Expectations in the Field of Gene Technology.” The presentation reviewed the development history of the gene industry and provided a comprehensive overview of the current corporate landscape. Using Sinovo Capital as a case study, it analyzed the future investment potential and expectations in gene technology. Finally, it conveyed BGI’s future goals through its innovative model of “tackling humanity’s ultimate questions with mega-projects.”

Rui Rui, Director of the Biomedical Division, Investment Promotion Center, Jintan Economic and Technological Development Zone

Rui Rui, Director of the Biopharmaceutical Division at the Investment Promotion Center of Jintan Economic and Technological Development Zone, delivered a presentation titled “Introduction to the Business Environment for the Synthetic Biology Industry in Jintan, Changzhou,” highlighting how Jintan District, as a “New Model for Beautiful Changzhou,” has introduced a comprehensive suite of supportive policies to foster the development of the new pharmaceutical industry.

Panel: The Value and Challenges of Industrializing Synthetic Biology

Finally, the event featured a panel discussion on “The Value and Challenges of Industrializing Synthetic Biology.” Representatives from leading synthetic biology companies—Jiyinda, Xinbeilai, and Redelin—along with investors from Miracle Light Venture Capital Fund and Mengniu Group’s venture capital arm, engaged in insightful discussions and shared their perspectives on core industrialization issues: product selection, large-scale manufacturing, and technological constraints on cost.

Concurrently, the 2023 XGI Life and Health Accelerator Camp kicked off with project roadshows, featuring presentations by six life sciences startups.

Blue Rainbow serves the biopharmaceutical industry through its unique “Industry + Incubation + Fund” integrated Innovation and Incubation 3.0 model. The Blue Rainbow Jintan Incubator will focus on biotech enterprises within the upstream and downstream supply chains of synthetic biology, facilitating the attraction of high-quality global biopharmaceutical projects to the Synthetic Biology Industrial Park. Leveraging Jintan’s comprehensive support policies designed to “boost the development of new pharmaceuticals,” and in synergy with the Changzhou Huasong Fund—which provides essential capital as a “source of living water” for building the industrial ecosystem—the incubator aims to ensure successful project implementation and jointly accelerate the development of the synthetic biology industry.

Swipe right to view more on-site photos